30. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, et al. (2003) Cross- priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009–1015. 31. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, et al. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715. 32. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710–722. 33. Harrington LE, Galvan M, Baum LG, Altman JD, Ahmed R (2000) Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med 191: 1241–1246. 34. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, et al. (2005) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125–1138. 35. Cretney E, Takeda K, Smyth MJ (2007) Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39: 280–286. 36. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199: 437–448. 37. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, et al. (2008) Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 105: 10895–10900. 38. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593–598. 39. Mokyr MB, Place AT, Artwohl JE, Valli VET (2006) Importance of signaling via the IFN-a/b receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Can Immunol Immunother 55: 459–468. 40. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM, et al. (2003) The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 63: 5143–5150. 41. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637–650. 42. Angulo I, Gomez de las Heras F, Garcia-Bustos JF, Gargallo D, Munoz- Fernandez MA, et al. (2000) Nitric oxide-producing CD11b+Ly-6G(Gr- 1)+CD31(ER-MP12)+ cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95: 212–220. 43. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL (2001) Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 166: 6608–6615. 44. North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71: 90–95. 45. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, et al. (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862–2868. Anti-Tumor Immune Response 46. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, et al. (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 336–344. 47. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 25: 111–118. 48. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, et al. (2007) Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergis- tically with cisplatin. Mol Cancer 6: 66. 49. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, et al. (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12: 693–698. 50. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782–798. 51. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, et al. (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 105: 11317–11322. 52. Brooks AD, Sayers TJ (2005) Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 54: 499–505. 53. Sayers TJ, Murphy WJ (2006) Combining proteasome inhibition with TNF- related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55: 76–84. 54. Weiland T, Weiller M, Kunstle G, Wendel A (2008) Sensitization by 5- Azacytidine towards death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 55. Fan Z, Yu P, Wang Y, Fu ML, Liu W, et al. (2006) NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 107: 1342–1351. 56. Park SY, Seol JW, Lee YJ, Cho JH, Kang HS, et al. (2004) IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 271: 4222–4228. 57. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, et al. (2003) Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22: 1653–1662. 58. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193: 661–670. 59. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, et al. (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis- inducing ligand-deficient mice. J Immunol 168: 1356–1361. 60. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, et al. (1999) Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162: 6658–6662. 61. Riviere Y, Gresser I, Guillon JC, Tovey MG (1977) Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc Natl Acad Sci U S A 74: 2135–2139. PLoS ONE | www.plosone.org 11 September 2009 | Volume 4 | Issue 9 | e6982